hotspot -WSS

hotspot

author：leisure time 2025-09-03 05:30:38 - browse：67642

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The Karikó problem: Lessons for funding basic research

WSS

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

What would happen to your eyes if you looked at the solar eclipse?

Why are elite athletes different? Take a look at their microbes

6 solutions to address cancer drug shortages and others

6 solutions to address cancer drug shortages and others

Stop Congress from blocking public access to science

focus

hotspot

explore

23andMe had bad news about my health. I wish a person had delivered it

Gene therapy has helped boys walk. Can scientists keep it that way?

DIEP, the 'gold standard' of breast reconstruction, is under threat

WATCH: Why do fingernails fall off when they're damaged?

Psychedelics group wrestles with new pharma identity

Ask STAT: What do you want to know about ChatGPT in medicine?

As demand for Covid shots wanes, Moderna seeks its next success

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Experts study whether long Covid risk adds up with each reinfection

Wikipedia

RSV injection headlines need to be accurate for good uptake

The Karikó problem: Lessons for funding basic research

Why are elite athletes different? Take a look at their microbes

The United States is paying nearly triple for new Covid vaccines

RSV injection headlines need to be accurate for good uptake

Will an HIV vaccine ever be a reality?

focus

Wikipedia

focus

hotspot